REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search-icon
News

Successful treatment of childhood leukemia with CAR T-cells

Successful treatment of childhood leukemia with CAR T-cells
In a first in Israel, Sheba Medical Center has achieved remission in a pediatric patient’s leukemia through CAR T-cell therapy. This innovative therapy is still only in clinical trials in the US, but has shown excellent results in over 70% of patients. Sheba is proud to be able to offer this effective treatment to our patients.

In Israel’s first and only such case, a child suffering from leukemia received CAR T-cell therapy and has achieved complete remission. This represents the first time that this treatment has been performed outside the United States. This innovative treatment is considered to be a breakthrough in the field of immunotherapy and in this case used CAR T-cells originally obtained from the patient’s own blood cells.

Cancer treatment using T-cells from the immune system first underwent research in Israel 25 years ago. The idea was to insert CSR receptors in the T-cells, thereby arming and directing them to act against specific markers on the cancer cells.

During the past five years, the first clinical trials of the CAR T-cell have shown unprecedented success. Teams led by the National Cancer Institute and other centers in the US have demonstrated complete resolution of refractory leukemia and recurrent leukemia in over 70% of patients. This therapy is now considered to be a cutting-edge immunotherapy treatment and is still given in the US only on a clinical trial basis.

Led by the Pediatric Hemato-Oncology Department and the Ella Lemelbaum Institute of Immuno-Oncology, CAR T-cell therapy was introduced at Sheba. Sheba was the first medical center outside of the US to utilize this innovative treatment successfully.

Prof. Amos Toren, Director of the Pediatric Hemato-Oncology Department, stated, “We are always proactive and up to date on the latest breakthroughs in the field in order to provide our patients with the most appropriate answer and the best available treatment. We have sent one of our finest specialists, Dr. Elad Jacoby, to learn the CAR T-cell technology at NIH in the US, and now we have brought it to Sheba. We are excited to receive such satisfactory results in our first patient.”

Sheba is excited to announce that it now offers the innovative CAR T-cell therapy for patients with Multiple Myeloma and is the first medical center in the world to pioneer its application for Acute Myelogenous Leukemia (AML) with 8:21 translocation and CD19 expression as part of a clinical study.

We also offer a full diagnostic procedure to determine whether this treatment is a suitable option for a patient.

Related
virtual care
Nuvo Group and Sheba Develop AI-Powered Gestational Diabetes Management Platform
A groundbreaking gestational diabetes pilot was recently completed by the two organizations, deploying Nuvo's INVU platform at Sheba’s Beyond Virtual Hospital, simplifying care for pregnant…
Read More
pain treatment for pancreatic cancer
Breakthrough Study: Radiation Therapy Effective for Pain Management in Cancer Patients
Pancreatic cancer, the 12th most common cancer worldwide, is associated with pain in approximately 75% of patients at the time of diagnosis, and as much…
Read More
arc center
News Nov 30.
Real-Time Detection of Cancerous Biomarkers With Artificial Intelligence
Lung cancer is the most common cancer and accounts for 1.76 million deaths per year worldwide. Non-small cell lung cancer (NSCLC) comprises 85% of all…
Read More